Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

BACKGROUND. Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. METHODS. We used stable isotopic labeling with deuterated water ((2)H(2)O) to measure directly the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Burger, Jan A., Li, Kelvin W., Keating, Michael J., Sivina, Mariela, Amer, Ahmed M., Garg, Naveen, Ferrajoli, Alessandra, Huang, Xuelin, Kantarjian, Hagop, Wierda, William G., O’Brien, Susan, Hellerstein, Marc K., Turner, Scott M., Emson, Claire L., Chen, Shih-Shih, Yan, Xiao-Jie, Wodarz, Dominik, Chiorazzi, Nicholas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256142/
https://ncbi.nlm.nih.gov/pubmed/28138560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados